Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Human growth hormone** is Lorven Biologics' recombinant human growth hormone product, a recombinant protein hormone intended for **growth disorders** and described by the company as also relevant to metabolic dysfunctions and age-related conditions. It acts as an **agonist of the growth hormone receptor**, mimicking endogenous human growth hormone to stimulate growth hormone signaling pathways that promote linear growth, tissue growth, cell regeneration, muscle growth, and metabolic effects. Based on the available company information, Lorven Biologics appears to position this product primarily as a **biopharmaceutical API manufactured under cGMP conditions** rather than as a disclosed clinical-stage branded medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human growth hormone.